Dexanabinol (HU-211) in the treatment of severe closed head injury: A randomized, placebo-controlled, phase II clinical trial

Critical Care Medicine

Volumn 30, Issue 3, 2002, Pages 548-554

  Knoller, Nachshon ^a   Levi, Leon ^b   Shoshan, Igal ^c   Reichenthal, Eli ^d   Razon, Nissim ^e   Rappaport, Zvi H ^f   Biegon, Anat ^g  

^a SHEBA MEDICAL CENTER   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e Ichilov Medical Centre   (Israel)

^f RABIN MEDICAL CENTER   (Israel)

^g PHARMOS LTD   (Israel)

Author keywords

Anti inflammatory; Antioxidant; Glasgow Coma Scale; Head trauma; HU 211; Intracranial pressure; N methyl D aspartate antagonist

Indexed keywords

DEXANABINOL;

ADULT; ARTICLE; BRAIN INJURY; BRAIN PERFUSION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLASGOW COMA SCALE; HEAD INJURY; HUMAN; INJURY SCALE; INTRACRANIAL PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0036192049     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200203000-00009     Document Type: Article

References (24)

1. The role of excitatory amino acids and NMDA receptors in traumatic brain injury
2. Cytokines in severe head trauma
3. The Kallikrein-kinin sytem as mediator in vasogenic brain edema
4. Novel pharmacologic strategies in the treatment of experimental traumatic brain injury
5. A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury
6. Effects of pegorgotein on neurologic outcome of patients with severe head injury: A multicenter, randomized controlled trial
7. Clinical neuroprotection trials in severe traumatic brain injury: Lessons from previous studies
8. Why have recent trials of neuroprotective agents in head injury failed to show convincing efficacy? A pragmatic analysis and theoretical considerations
9. Enantiomeric cannabinoids: Stereospecificity of psychotropic activity
10. Nonpsychotrophic cannabinoid acts as a functional NMDA receptor blocker
11. Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist
12. Cytokine production in the brain following closed head injury: Dexanabinol (HU-211) is a novel TNF-a inhibitor and an effective neuroprotectant
13. Protection against septic shock and suppression of tumor necrosis factor α and nitric oxide production by dexanabinol (HU-211), a non-psychotropic cannabinoid
14. Long-term effect of HU-211, a novel non-competitive NMDA antagonist, on motor and memory functions after closed head injury in the rat
15. HU-211, a novel non-competitive NMDA antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat
16. HU-211, a non-psychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy
17. Development of HU-211 as a neuroprotectant for ischemic brain damage
18. Clinical pharmacokinetics of escalating i.v. doses of dexanabinol (HU-211), a neuroprotectant agent, in normal volunteers
19. A new classification of head injury based on computerized tomography
20. Guidelines for the management of severe head injury
21. Prognosis after acute subdural and epidural haemorrhage
22. MRI study of rat brain edema after head trauma: Effects of HU-211, a nonpsychotropic cannabinoid
23. The outcome of severe closed head injury
24. A randomized trial of nimodipine in severe head injury: HIT 1